The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world impact of metabolic, renal, and demographic factors on overall survival in well- to moderately differentiated gastrointestinal and pancreatic neuroendocrine tumors.
 
Emily Toegel
No Relationships to Disclose
 
Benjamin Ueberroth
No Relationships to Disclose
 
Christopher Lieu
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Genentech (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst)
 
Christos Fountzilas
Consulting or Advisory Role - Astellas Pharma (Inst)
Research Funding - Amgen (Inst); Aravive (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); CrystalGenomics (Inst); Daiichi Sankyo (Inst); ERYTECH Pharma (Inst); Imugene (Inst); Ipsen (Inst); Legend Biotech USA Inc (Inst); Merck (Inst); Pfizer (Inst); Revolution Medicines (Inst); Sanofi (Inst); Taiho Oncology (Inst); Torl Biotherapeutics (Inst); TransThera Biosciences (Inst); Valar Labs (Inst)
 
Melissa Fishel
Patents, Royalties, Other Intellectual Property - Patent: Use of APE1/Ref-1 inhibitors for treatment of retinal disease. Mark Kelley and Melissa L. Fishel, Patent no,: US 12,350,247 B2 Issued July8, 2025.
 
Robert Rounbehler
No Relationships to Disclose
 
Michael Cavnar
No Relationships to Disclose
 
Dae Won Kim
Honoraria - Ipsen
 
Michelle Churchman
No Relationships to Disclose
 
Hassan Hatoum
Consulting or Advisory Role - AstraZeneca; Exelixis
Research Funding - Natera (I)
 
Sunnie Kim
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol Myers Squibb; Coherus Biosciences; Daiichi Sankyo/Lilly; Gilead Sciences; I-Mab; Jazz Pharmaceuticals; Merck
Research Funding - Merck
 
Wells Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Amgen; Criterium (Inst)
Research Funding - Accent Therapeutics; Agenus (Inst); ALX Oncology (Inst); AstraZeneca/MedImmune (I); Exelixis (Inst); Experimental Drug Development Centre (EDDC); Nurix (Inst); Pfizer (Inst); RasCal (Inst); Revolution Medicines (Inst)
 
Hannah Robinson
Research Funding - ArriVent BioPharma, Inc. (Inst); Genentech (Inst); GlaxoSmithKline (Inst)
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Seagen (Inst); Sensei Biotherapeutics (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
Tiago Biachi de Castria
Consulting or Advisory Role - AstraZeneca; Bayer; Moderna Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Astellas Pharma (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Ipsen; Moderna Therapeutics